Evidence map›Paper›PMID 34867354›Full record

ArticleFrontiers in pharmacology2021

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity

Oksana Montecchini, Stefania Braidotti, Raffaella Franca, Giulia Zudeh, Christian Boni, Claudio Sorio, Eleonora Toffoletti, Marco Rabusin, Alberto Tommasini, Giuliana Decorti and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Oksana MontecchiniDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Stefania BraidottiDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Raffaella FrancaDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Giulia ZudehDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Christian BoniDepartment of Medicine, University of Verona, Verona, Italy.
Claudio SorioDepartment of Medicine, University of Verona, Verona, Italy.
Eleonora ToffolettiDivision of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria, Udine, Italy.
Marco RabusinInstitute for Maternal and Child Health (I.R.C.C.S) Burlo Garofolo, Trieste, Italy.
Alberto TommasiniDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Giuliana DecortiDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Gabriele StoccoDepartment of Life Sciences, University of Trieste, Trieste, Italy.
University of Trieste · ITIRCCS Materno Infantile Burlo Garofolo · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathogenic role of the overactivated ABL1 tyrosine kinase (TK) pathway is well recognized in some forms of

Indexed as

ABL1-class BCR-ABL1 like acute lymphoblastic leukemiaABL1 peptide biosensorABL1 tyrosin kinase inhibitorsin vitro ELISA assayprecision therapy

Identifiers

PMID34867354
PMCPMC8640483
OpenAlexW3216963885

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.